Great Basin Scientific Inc. (fka GBSNQ)

[Steve1HD1]

Hello GBSN $$$ fans, wake up .... interesting research from other board ...>

... The 2 FDA approvals should - bring up to 300 million $$$ annual turnover ...

2) In addition to two already-approved tests, Great Basin has
initiated clinical trials in preparation for FDA 510(k) marketing
clearance: A) Staph blood infections (Staph ID/R), a potential $100-
$150 million annual market in the US, and B) Shiga Toxin Producing
E. Coli (STEC) test, also an approximate $100-$150 million US
market. Marketing approvals for these next two diagnostic assays are
expected to be filed in 2015 with potential clearance sometime this year
or next. In addition, the Company has identified three additional assays
for next-step clinical trials, including two in the higher-revenue multiplex
panel category, with the other for the large-market size Staph
aureus pre-surgical screening assay.
3) After completing a somewhat smaller-size IPO last year, Great
Basin management can finally breathe easier regarding its longterm
business plan following a recent, much larger equity raise
earlier this year. In addition to the $21.7 million in approximate gross
proceeds garnered from the February 2015 preferred stock offering, the
Company has been able to raise additional funds through the
subsequent exercise of warrants, and may continue to do so in the
future depending on share price and volume. This additional cash is
key to the Company’s growth going forward, fueling not only greater
sales and marketing budgets, but increased inventories of both analyzer
instruments (provided free of charge to customers) and disposable
cartridges, as customer usage of Great Basin’s proprietary molecular
diagnostic tests increase.


http://dawsonjames.com/portal/GBSN%20Initiation%205%2026%202015.pdf